Summary of Results: Solid Tumours and Haematological Malignancies

Survival is a crucial indicator for the observation and epidemiological surveillance of cancer along with incidence, mortality and prevalence. It allows to assess the overall improvement in the prognosis of people diagnosed with cancer, resulting from both therapeutic progress and actions implemented to diagnose cancers at earlier stages and to improve their management. Survival is essential to evaluate the health system and to measure the impact of public policies in terms of prevention, screening, and care.

This fourth survival study, based on data from the Francim network's metropolitan cancer registries, is in line with the objectives of the various cancer plans and the Ten-Year Cancer Control Strategy 2021-2030, particularly the axis related to the fight against poor prognosis cancers. It is the result of a partnership between the French cancer registries network (FRANCIM), the Biostatistics-Bioinformatics Department of the Hospices civils de Lyon (HCL), Santé Publique France and the French National Cancer Institute (INCa).

This new study provides updated survival estimates at 1, 5 and 10 years after a cancer diagnosis, as well as changes in survival since 1989. In addition, for the first time, 20-year post-diagnosis survival estimates are presented along with estimates by anatomical or histological subsites.

This summary presents the key aspects of the methodology used and focuses on the main findings. The tables and figures presented in this summary will give a glimpse of their specificities. It was chosen to comment on the findings for solid tumours and haematological malignancies altogether.

Please consult our Survie des personnes atteintes de cancer en France métropolitaine section (in French) for further information.